DOCSLIB.ORG

LF-105085-01 Cyclizine Hcl 50Mg Tabs V2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LF-105085-01 Cyclizine Hcl 50Mg Tabs V2 28053233 Package leaflet: Information for the patient • an increased sensitivity to sunlight LF-105085-01 (photosensitivity) • inflammation of the liver (hepatitis) or problems with the liver • reduced rate of breathing (apnoea) Cyclizine Hydrochloride 50 mg Tablets • reduction in the production of a type of spasm, involuntary movements, convulsions, white blood cell making infection more Cyclizine Hydrochloride high temperature and difficulty breathing. likely (agranulocytosis). If you take more Cyclizine Hydrochloride Tablets If you feel very tired, experience unexpected Read all of this leaflet carefully before you • have epilepsy than you should, contact your doctor or nearest bruising or bleeding or more infections (e.g. start taking this medicine because it • are a man and you suffer from an enlarged hospital emergency department immediately. colds and sore throats) than usual please tell contains important information for you. prostate gland (difficulty or slowness Remember to take this leaflet and/or the package your doctor. Your doctor may decide to • Keep this leaflet. You may need to read it passing urine) with you to show the doctor what you have taken. conduct tests on your blood periodically as a again. • have been told your heart is not working result of these symptoms. • If you have any further questions, ask your properly (heart failure) If you forget to take Cyclizine Hydrochloride doctor, pharmacist or nurse. • suffer from an inherited disorder which Tablets If any of the side effects becomes severe or • This medicine has been prescribed for you can lead to a sensitivity to sunlight If you forget to take a dose, just take the next dose you notice any side effects not listed in this only. Do not pass it on to others. It may (porphyria). at the usual time, DO NOT take a double dose to leaflet please tell your doctor or pharmacist make up for a forgotten tablet. immediately. harm them, even if their signs of illness Other medicines and Cyclizine Hydrochloride are the same as yours. Tablets 4. POSSIBLE SIDE EFFECTS Reporting of side effects • If you get any side effects, talk to your Tell your doctor or pharmacist if you are Like all medicines, this medicine can cause If you get any side effects, talk to your doctor, doctor, pharmacist or nurse. This includes taking, have recently taken or might take any side effects, although not everybody gets pharmacist or nurse. This includes any any possible side effects not listed in this other medicines especially the following: them. possible side effects not listed in this leaflet. leaflet. See section 4. • medicines for problems such as You can also report side effects directly via the The name of your medicine is Cyclizine If you notice: depression, anxiety or difficulty in Yellow Card Scheme, website: Hydrochloride 50 mg Tablets. It will be • itching or skin rashes sleeping www.mhra.gov.uk/yellowcard or search for referred to as Cyclizine Hydrochloride Tablets • swelling of the face, lips or throat • strong painkillers such as pethidine MHRA Yellow Card in the Google Play or Apple for ease hereafter. • difficulty in breathing or wheeziness • any medicine which belong to a group of App Store. stop taking this medicine and tell your doctor What is in this leaflet medicines called anticholinergics. By reporting side effects, you can help provide immediately. These may be signs of an 1. What Cyclizine Hydrochloride Tablets are more information on the safety of this Cyclizine Hydrochloride Tablets with food allergic reaction. and what they are used for and drink medicine. 2. What you need to know before you take Alcohol should be avoided when you are The following side effects are reported with a Cyclizine Hydrochloride Tablets taking Cyclizine Hydrochloride Tablets. not known frequency (frequency cannot be 5. HOW TO STORE CYCLIZINE HYDROCHLORIDE 3. How to take Cyclizine Hydrochloride Tablets estimated from the available data): TABLETS Pregnancy and breast-feeding 4. Possible side effects • skin rashes or itching Keep this medicine out of the sight and reach If you are pregnant or breast-feeding, think you 5. How to store Cyclizine Hydrochloride Tablets • drowsiness of children. may be pregnant or are planning to have a baby, 6. Contents of the pack and other information • lack of coordination Do not use this medicine after the expiry date ask your doctor or pharmacist for advice before • headache which is stated on the carton and label after taking this medicine. 1. WHAT CYCLIZINE HYDROCHLORIDE • a dry mouth, nose or throat EXP. The expiry date refers to the last day of TABLETS ARE AND WHAT THEY ARE Driving and using machines • blurred vision that month. USED FOR You can drive while taking Cyclizine • involuntary rolling of the eyes Store this medicine in a safe place below 25°C. Cyclizine Hydrochloride Tablets contain the active Hydrochloride Tablets but do not drive until • fast heartbeat Do not throw away any medicines via substance cyclizine hydrochloride, which belongs you know how the tablets affect you. Cyclizine • irregular heartbeat to a group of medicines called antihistamines wastewater or household waste. Ask your Hydrochloride Tablets may make you feel • difficulty in passing water pharmacist how to throw away medicines you which can be used to help stop you feeling sick dizzy. If they affect you in this way, do not • constipation (nausea) or being sick (vomiting). no longer use. These measures will help drive or operate any machinery. • heartburn (reflux) protect the environment. Cyclizine Hydrochloride Tablets may be used Cyclizine Hydrochloride Tablets contain • feeling sick by adults and children aged 6 years and over. lactose. • being sick 6. CONTENTS OF THE PACK AND OTHER Cyclizine Hydrochloride Tablets may be used if If you have been told that you have • diarrhoea INFORMATION you suffer from travel or motion sickness; intolerance to some sugars, talk to your • stomach pain What Cyclizine Hydrochloride Tablets nausea caused by cancer treatment doctor before taking these tablets. • loss of appetite contains (radiography) or other medicines; or if you • restlessness Each tablet contains 50 mg of the active have had an operation, as general anaesthetics 3. HOW TO TAKE CYCLIZINE HYDROCHLORIDE • nervousness ingredient, cyclizine hydrochloride. The other can sometimes cause sickness. TABLETS • euphoria ingredients include: lactose, potato starch, Cyclizine Hydrochloride Tablets can also be Always take this medicine exactly as your • difficulty in sleeping acacia and magnesium stearate. used to treat sickness caused by some inner doctor or pharmacist has told you. • ringing in the ears ear problems such as Meniere’s disease. Check with your doctor, pharmacist or nurse if • seeing or hearing things that are not really What Cyclizine Hydrochloride Tablets look you are not sure. there (hallucinations) like and contents of the pack 2. WHAT YOU NEED TO KNOW BEFORE YOU Cyclizine Hydrochloride Tablets are white with Adults • decrease in muscle tone TAKE CYCLIZINE HYDROCHLORIDE TABLETS a single score line and the marking “T4A” on The recommended dose is one tablet up to • unusual body movements, particularly of Do not take Cyclizine Hydrochloride Tablets: the same side. They are available in bottles of three times daily. your hands, arms or legs • if you are allergic to cyclizine • muscle twitches, spasms or tremors 100 tablets. hydrochloride or any of the other Use in children and adolescents. • seizures Marketing Authorisation Holder and ingredients of this medicine (allergic Children over 12 years • being confused, disorientated or unaware Manufacturer reactions include mild symptoms such as The recommended dose is one tablet up to • dizziness Amdipharm UK Limited, itching and / or rash. More severe three times daily. • feeling weak Capital House, 85 King William Street, symptoms include swelling of the face, • decreased consciousness Children from 6 to 12 years London EC4N 7BL, UK lips, tongue and / or throat with difficulty • temporary difficulty in speaking in swallowing or breathing) The recommended dose is half a tablet up to three times a day. The tablet can be divided • high blood pressure Alternative Site for batch release: • if you have been drinking alcohol. The • low blood pressure anti-vomiting properties of cyclizine may into equal doses along the line scored on one CENEXI SAS, side of the tablet. • pins and needles 52 Rue Marcel et Jacques Gaucher, 94120, increase the toxicity of alcohol. • yellowing of the skin and the whites of Children under 6 years Fontenay sous Bois, France your eyes (jaundice) Warnings and precautions Do not give this medicine to children under the • a red or brownish patch which appears at This leaflet was last revised in June 2018. Talk to your doctor, pharmacist or nurse age of 6. before taking Cyclizine Hydrochloride the same spot each time you take the Tablets if you: The tablets should be swallowed with a little medicine • suffer from an eye disease caused by a water. rise of pressure within the eye (glaucoma) If you take more Cyclizine Hydrochloride • suffer from urinary retention (experience Tablets than you should difficulty passing urine) Symptoms of overdose include dry mouth, • have an obstructive bowel condition nose and throat, blurred vision, fast or • have any liver problems irregular heartbeat, difficulty passing urine, • suffer from phaeochromocytoma (tumour drowsiness, dizziness, lack of balance and of the medulla of the adrenal glands) coordination, weakness, excitability, disorientation, • suffer from high blood pressure impaired judgement, hallucinations, muscle 125 mm 15 mm 35 mm • an increased sensitivity to sunlight (photosensitivity) • inflammation of the liver (hepatitis) or problems with the liver • reduced rate of breathing (apnoea) • reduction in the production of a type of spasm, involuntary movements, convulsions, white blood cell making infection more high temperature and difficulty breathing. likely (agranulocytosis). If you take more Cyclizine Hydrochloride Tablets If you feel very tired, experience unexpected Read all of this leaflet carefully before you • have epilepsy than you should, contact your doctor or nearest bruising or bleeding or more infections (e.g.
Load more

Recommended publications
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the Use of Antiemetics Author(S): Dr Annette Edwards (Chai
    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the use of Antiemetics Author(s): Dr Annette Edwards (Chair) and Deborah Royle on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group Overall objective : To provide guidance on the evidence for the use of antiemetics in specialist palliative care. Search Strategy: Search strategy: Medline, Embase and Cinahl databases were searched using the words nausea, vomit$, emesis, antiemetic and drug name. Review Date: March 2008 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group. They are intended to be used by qualified, specialist palliative care professionals as an information resource. They should be used in the clinical context of each individual patient’s needs. The clinical guidelines group takes no responsibility for any consequences of any actions taken as a result of using these guidelines. Contact Details: Dr Annette Edwards, Macmillan Consultant in Palliative Medicine, Department of Palliative Medicine, Pinderfields General Hospital, Aberford Road, Wakefield, WF1 4DG Tel: 01924 212290 E-mail: [email protected] 1 Introduction: Nausea and vomiting are common symptoms in patients with advanced cancer. A careful history, examination and appropriate investigations may help to infer the pathophysiological mechanism involved. Where possible and clinically appropriate aetiological factors should be corrected. Antiemetics are chosen based on the likely mechanism and the neurotransmitters involved in the emetic pathway. However, a recent systematic review has highlighted that evidence for the management of nausea and vomiting in advanced cancer is sparse. (Glare 2004) The following drug and non-drug treatments were reviewed to assess the strength of evidence for their use as antiemetics with particular emphasis on their use in the palliative care population.
    [Show full text]
  • The Use of Cyclizine in Patients Receiving Parenteral Nutrition
    DRAFT - The use of cyclizine in patients receiving parenteral nutrition Jeremy Nightingale, Uchu Meade, Gavin Leahy and the BIFA committee Cyclizine is a piperazine derivative that was discovered in 1947 while researching new antihistamine drugs (H1 blockers) and was first sold 1965. It is marketed for the treatment or prevention of nausea, vomiting, and labyrinthine disorders including vertigo and motion sickness. This includes nausea after a general anaesthetic and that caused by opioid use. In the United Kingdom the oral formulation is classified as a Pharmacy (P) medicine and can be sold from a registered pharmacy premises by or under the supervision of a pharmacist. The intravenous formulation is classified as a Prescription Only Medicine (POM). There is increasing recognition that the intravenous formulation of cyclizine may cause euphoria and dependence (addiction); these side effects may not be reported by patients and be under recognised by healthcare professionals. It has many associated problems when used by patients receiving long-term parenteral nutrition. This position paper highlights the risks associated with its long-term intravenous use. Actions/pharmacology (1) Cyclizine has both anti-histamine (H1) and anti-cholinergic (anti-muscarinic M1) effects. It is a class 1 drug in the biopharmaceutical classification (high permeability and solubility) with a peak plasma concentration of about 70 ng/ ml reached approximately 2 hours after oral ingestion, as measured in healthy adult patients. Its quoted elimination (biological) half-life is 20 hours when given orally (1) and 13 hours when given intravenously (2). Cyclizine is metabolised to its N-demethylated derivative, norcyclizine, which has little anti-histaminic (H1) activity compared to cyclizine.
    [Show full text]
  • Motion Sickness Traveler Summary Key Points Motion Sickness Consists of a Group of Signs and Symptoms That Develop in Response to Real Or Perceived Motion
    Motion Sickness Traveler Summary Key Points Motion sickness consists of a group of signs and symptoms that develop in response to real or perceived motion. Symptoms include dizziness, nausea, and vomiting. Prevention includes: Eating light meals Avoiding alcohol Sitting in the front seat of a car, over the wings on an airplane, or mid-deck on ships and facing forward in buses and trains Avoiding tasks requiring a close focus (e.g., reading) Using over-the-counter (OTC) or prescription medication OTC medications include: Dimenhydrinate, diphenhydramine, cyclizine, or meclizine: take 1 hour before departure and continue during the trip. These medications can cause sedation; do not mix with alcohol. Read labels carefully. Check for cautions regarding use in certain conditions. Prescription medications include: Scopolamine patches: place behind the ear; change every 3 days; apply 8 hours before the first incidence of rough weather or rough roads. Dry mouth and dry eyes may result. Patches do not work if cut in half. More than 1 patch should never be applied; hallucinations or psychosis may result. Strong sedatives (such as promethazine or prochlorperazine): take orally or by suppository after onset of severe symptoms, but anticipate sleep for a number of hours. A cruise medical clinic may administer injectable promethazine if absolutely necessary. Introduction The human body has a delicate system of equilibrium that relies on fluids in the inner ear, visual sensors, and other physical input to maintain a sense of balance. When incoming signals are in conflict—for example, when the body is at rest yet the eyes sense movement—this system is disturbed, causing the symptoms of motion sickness.
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]
  • Post‐Operative Nausea & Vomiting ‐ Use of Anti‐Emetic
    © 2012 Scottish Universities Medical Journal, Vol 1 Issue 1: page 89-97 Dundee Published online: Feb 2012 Rother C ‘Post-Operative Nausea & Vomiting – use of anti-emetic agents in anaesthesia’ Post‐Operative Nausea & Vomiting ‐ Use of Anti‐Emetic Agents in Anaesthesia Catriona Rother (4th Year MBChB, BMSc) University of Dundee Correspondence to: [email protected] ABSTRACT Post‐operative nausea and vomiting (PONV) is a recurrent problem in the field of anaesthetics. It is usually defined as nausea, retching or vomiting within 24 hours of surgery and affects 20‐30% of patients. Although often considered merely an unpleasant side effect of general anaesthesia or surgery, PONV can result in many unwanted and potentially serious outcomes and increases healthcare expenditure considerably. Background Post‐operative nausea and vomiting (PONV) usually defined as nausea, retching or vomiting within 24 hours of surgery and affects 20‐30% of patients.1, 2, 3 PONV is an important problem and can lead to potentially serious outcomes and an increase healthcare expenditure.2 Post‐operative nausea and vomiting increases recovery room time, requiring expanded levels of nursing care,4, 5 and delays mobilisation following surgery as movement often exacerbates PONV.3 As a result, the early discharge of ambulatory surgery patients is frequently delayed,1 with around 1% requiring overnight admission.6 Persistent vomiting can result in dehydration, electrolyte imbalance and metabolic alkalosis.7, 8 The oral administration of drugs, nutrition and fluids may also be delayed5 and the level of post‐operative analgesia that can be obtained may be limited if effective doses of opiate cannot be administered orally.
    [Show full text]
  • Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)
    Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects
    [Show full text]
  • Guidelines for the Management of Nausea and Vomiting in Palliative Care
    GUIDELINES FOR THE MANAGEMENT OF NAUSEA AND VOMITING IN PALLIATIVE CARE 27.1 GENERAL PRINCIPLES Nausea and vomiting are experienced by 50-60% of patients with advanced cancer. 1 Nausea and vomiting are more common in certain groups of patients i.e. <65 years old, females and certain malignancies e.g. gastric and breast cancer. 1 Patients with advanced malignancy may develop nausea and vomiting from causes unrelated to the cancer e.g. gall bladder disease or gastroenteritis. 1 Table 27.1 lists some common causes of nausea and vomiting in patients with advanced cancer. 1, 2 1, 2 Table 27.1 Common causes of nausea and vomiting in advanced cancer Anxiety Gastritis Autonomic neuropathy Hypercalcaemia Biochemical Infection Brainstem / meningeal disease Intestinal obstruction Constipation Pain Cough Radiotherapy Drugs Raised intracranial pressure Functional obstruction Renal failure Gastric outlet obstruction Vestibular disturbance Anti-emetics are neurotransmitter-blocking agents and are effective at different receptor sites (see Figure 27.1). 3 The choice of anti-emetic will be influenced by the cause of vomiting. They may be administered by a variety of routes. The oral or subcutaneous routes are the preferred options in palliative care. 4 27.2 GUIDELINES Table 27.2 lists the pharmacological options for the management of nausea and vomiting in advanced cancer. 3 Table 27.2 Pharmacological options for the management of nausea and vomiting in advanced cancer 1, 2, 3, 5, 6 [Level 4] Drug name Type of drug Indication for Oral dose Parenteral dose Parenteral dose Notes use (subcutaneously over (subcutaneous stat 24 hours via a syringe doses) driver) Cyclizine Antihistamine Central causes.
    [Show full text]
  • The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum
    The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum Green-top Guideline No. 69 June 2016 The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum This is the first edition of this guideline. Executive summary of recommendations Diagnosis of nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum (HG) How is NVP diagnosed? NVP should only be diagnosed when onset is in the first trimester of pregnancy and other causes of D nausea and vomiting have been excluded. How is HG diagnosed? HG can be diagnosed when there is protracted NVP with the triad of more than 5% prepregnancy D weight loss, dehydration and electrolyte imbalance. How can the severity of NVP be classified? An objective and validated index of nausea and vomiting such as the Pregnancy-Unique C Quantification of Emesis (PUQE) score can be used to classify the severity of NVP. What initial clinical assessment and baseline investigations should be done before deciding on treatment? Clinicians should be aware of the features in history, examination and investigation that allow NVP and HG to be assessed and diagnosed and for their severity to be monitored. P What are the differential diagnoses? Other pathological causes should be excluded by clinical history, focused examination and investigations. P What is the initial management of NVP and HG? How should the woman be managed? Women with mild NVP should be managed in the community with antiemetics. D Ambulatory daycare management should be used for suitable patients when community/primary C care measures have failed and where the PUQE score is less than 13.
    [Show full text]
  • Safety and Efficacy of Doxylamine Succinate 10Mg with Pyridoxine Hydrochloride 10Gs (Diclectin) for Nausea and Vomiting of Pregnancy (N.V.P)
    Safety and Efficacy of Doxylamine Succinate 10mg with Pyridoxine Hydrochloride 10gs (Diclectin) for Nausea and Vomiting of Pregnancy (N.V.P) 1. Careful questioning of the patient, early in pregnancy, about the frequency and intensity of the symptoms of nausea and vomiting allows the practitioner to intervene with diet and lifestyle adjustments, as well as medication with the aim of preventing hyperemesis gravidarum. Doxylamine Succinate 10mg, in combination with Pyridoxine Hcl 10mg (Diclectin), were approved for use in the treatment of nausea and vomiting in pregnancy by the Health Protection Branch of Health and Welfare Canada in 1990. To date, this formulation is the only anti-nauseant approved for such use. Bendectin (Diclectin) which was withdrawn from the market in 1983 in the USA after several unsuccessful lawsuits against it. Despite the most vigorous testing of any drug in pregnancy, no evidence of teratogenicity has been found. Multiple studies have reviewed Debendox (Bendectin, Diclectin) and concluded that the drug is a safe effective treatment for nausea and vomiting of pregnancy and that there is no evidence that it is a teratogen. Doxylamine Succinate in combination with Pyridoxine Hcl 10mg (Diclectin) is a delayed release tablet. It is recommended that they start with two tablets at night before bed. If symptoms are not relieved, one tablet in the morning and another mid-afternoon can be added. The dosing regime can be tailored to fit each woman’s peak of symptoms. It is recommended that all health professionals should question women early in their pregnancies about the presence of these symptoms, and offer intervention, with advice about diet, lifestyle adjustment and medical treatment.
    [Show full text]
  • The Association of Paediatric Anaesthetists of Great Britain & Ireland
    Autumn 2016 The Association of Paediatric Anaesthetists of Great Britain & Ireland Guidelines on the Prevention of Post-operative Vomiting in Children Contributing Authors: Simon Martin David Baines Helen Holtby Alison S Carr Guidelines on the Prevention of Postoperative Vomiting in Children Members of the 2016 Guidelines Revision Group: Dr Simon Martin Consultant Paediatric Anaesthetist Plymouth Hospitals NHS Trust Derriford Hospital Plymouth Professor Alison S Carr Consultant Paediatric Anaesthetist Head of Clinical Education & Professor College of Medicine Qatar University PO Box 2713 Doha, Qatar Dr David Baines Clinical Associate Professor Head, Department of Anaesthesia The Children's Hospital at Westmead NSW Australia Dr Helen Holtby Staff Anesthesiologist Division of Cardiac Anesthesia Department of Anesthesia and Pain Medicine SickKids Hospital, Toronto Additional Contributing Authors of 2009 Guideline Simon Courtman Neil Morton Scott Jacobson Liam Brennan Per-Arne Lönnqvist Jackie Pope 3 Contents Page No. Key to evidence statements and grades of recommendation 4 Introduction 5 Remit of the guideline Glossary 7 1. Identifying children at high risk of postoperative vomiting (POV) 8 A. Patient factors 8 Age, history of POV, motion sickness, gender, preoperative anxiety, smoking B. Surgical Factors 10 Duration of surgery, type of surgery C. Anaesthetic Factors 12 Nitrous oxide, volatile agents, peri-operative opioids, anticholinesterases, peri-operative fluids 2. Pharmacological treatment of POV in children A. Anti-emetics for prevention & reduction of POV in children 14 Single Agents: 14 5HT3 Antagonists, Dexamethasone, Metoclopramide, Prochlorperazine, Cyclizine, Dimenhydrinate Combination Therapy: 24 Ondansetron and dexamethasone, Ondansetron and other combination anti-emetic therapy, Tropisetron B. Anti-emetics for treating established POV in children 25 3.
    [Show full text]